RESULTS

- 46 patients of SCC Supraglottis underwent TORS from February, 2014 to May, 2016 were included in the study.

- Table 2: Demographic characteristics of the patients (n=46).

- Table 3: Clinicopathological details of the patients (n=46).

- Table 4: Outcomes.

- Table 5: Functional outcomes.

- Table 6: Adverse events.

- Table 7: Oncological Follow-up.

- Overall survival was 94.9% with disease free survival of 88.5% at mean follow-up of 15 months.

- CONCLUSION

- This is a first of its kind single institutional study which evaluated the feasibility, safety, functional outcome and oncological outcome in HPV negative supraglottic SCC. This study demonstrated that TORS provided an early primary stage supraglottic SCC is feasible and safe, with good functional and oncological outcome. It has the least morbidity and offers benefits in terms of early airway and feeding rehabilitation and can avoid complications resulting from radiation therapy for these patients. Long-term oncological outcome and 5 year survival still need to be evaluated for TORS SCC.

Contact Information:
Presenter: Dr. Karan Gupta, MS, DNB
Institute: Rajiv Gandhi cancer Institute and Research Centre, India.
E-mail: Guptaakaran@gmail.com